Notice to Our Patients Regarding a Stolen Briefcase. Learn More
Find a Doctor
Cancer Focus: Anal Cancer, Appendiceal (Appendix) Cancer, Cholangiocarcinoma (Bile Duct Cancer), Colon Cancer, Colorectal Cancer , Esophageal Cancer , Gallbladder Cancer , Gastrointestinal Carcinoid Tumor , Liver Cancer , Pancreatic Cancer , Rectal Cancer , Stomach (Gastric) Cancer
Dr. Haider is an Assistant Member of the Moffitt Medical Group faculty based at Tampa General Hospital (TGH). Dr. Haider received her Bachelor of Science and Medical Degree at the University of Florida in Gainesville, FL. She completed an internship followed by residency in Internal Medicine at the University of Southern California in Los Angeles, CA. She completed a Hematology and Medical Oncology Fellowship at the University of South Florida and Moffitt Cancer Center in Tampa, FL. Her clinical practice at TGH is comprehensive and includes benign and malignant hematology as well as medical oncology. Dr. Haider’s academic interests encompass clinical research focused on the treatments of gastrointestinal and hepatobiliary malignancies. She is a Clinical Educator in the Department of Satellite Oncology, where she also participates in the education of medical students, residents and fellows.
Education & Training
- Internal Medicine
- University of South Florida - Hematology and Medical Oncology
- University of Southern California - Internal Medicine
- University of Florida College of MedicineMD
- Strosberg JR, Al-Toubah T, Pellè E, Smith J, Haider M, Hutchinson T, Fleming JB, El-Haddad G. Risk of bowel obstruction in patients with mesenteric/peritoneal disease receiving peptide receptor radionuclide therapy (PRRT). J Nucl Med. 2020 May. Pubmedid: 32444368.
- Zhang Q, Haider M, Al Ali NH, Lancet JE, Epling-Burnette PK, List AF, Padron E, Komrokji RS. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2020 Jun.20(6):400-406.e2. Pubmedid: 32179032.
- Haider M, Al-Toubah T, El-Haddad G, Strosberg J. Molecular imaging and radionuclide therapy of neuroendocrine tumors. Curr Opin Endocrinol Diabetes Obes. 2020 Feb.27(1):16-21. Pubmedid: 31789833.
- Al-Toubah T, Strosberg J, Halfdanarson T, Oleinikov K, Gross DJ, Haider M, Sonbol MB, Almquist D, Grozinsky-Glasberg S. Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia. Chest. 2020 Feb.158(1):401-405. Pubmedid: 32059961.
- Haider M, Duncavage EJ, Afaneh KF, Bejar R, List AF. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. Am Soc Clin Oncol Educ Book. 2017 Dec.37:480-494. Pubmedid: 28561687.
- Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S44-S48. Pubmedid: 27521323.
- Aldoss I, Ji L, Haider M, Pullarkat V. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia. Acta Haematol. 2014 Jul.131(4):202-207. Pubmedid: 24296475.
- Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012 Apr.78(14):1096-1099. Pubmedid: 22474298.
- Tzachanis D, Haider M, Papazisis G. A Case of Subacute Encephalopathy Developing After Treatment With Clofarabine and Methotrexate That Resolved With Corticosteroids. Am J Ther. 23(3):e937-e940. Pubmedid: 24987945.
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.Learn more about our patient comments
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
- The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
- He or she may be a researcher or other type of provider that does not see patients.
- The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.